{"id":1925,"date":"2012-03-01T12:09:00","date_gmt":"2012-03-01T11:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/antithrombotische-dreifachtherapie-bei-kardiovaskulaeren-risikopatienten"},"modified":"2022-03-17T14:12:20","modified_gmt":"2022-03-17T13:12:20","slug":"antithrombotische-dreifachtherapie-bei-kardiovaskulaeren-risikopatienten","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/antithrombotische-dreifachtherapie-bei-kardiovaskulaeren-risikopatienten","title":{"rendered":"Antithrombotische Dreifachtherapie bei kardiovaskul\u00e4ren Risikopatienten"},"content":{"rendered":"<p>Zusammenfassung: Eine antithrombotische Dreifachtherapie, bestehend aus einem oralen Antikoagulans (z.B. Phenprocoumon, Warfarin) plus dualer Hemmung der Thrombozytenaggregation, sollte wegen des hohen Blutungsrisikos m\u00f6glichst vermieden werden. Patienten mit chronischem Vorhofflimmern und Indikation zur oralen Antikoagulation sollten daher bei einem akuten Myokardinfarkt oder bei akutem Koronarsyndrom (ACS) nur im Ausnahmefall einen beschichteten Koronar-Stent (Drug eluting stent = [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Eine antithrombotische Dreifachtherapie, bestehend aus einem oralen Antikoagulans (z.B. Phenprocoumon, Warfarin) plus dualer Hemmung der Thrombozytenaggregation, sollte wegen des hohen Blutungsrisikos m\u00f6glichst vermieden werden. Patienten mit chronischem Vorhofflimmern und Indikation zur oralen Antikoagulation sollten daher bei einem akuten Myokardinfarkt oder bei akutem Koronarsyndrom (ACS) nur im Ausnahmefall einen beschichteten Koronar-Stent (Drug eluting stent = [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,74,684,495,137,1322,60,4153,184,77,76,2088,4152,73,2305,1314,1312,4154,71,187,68,1172,498,65,1328,1327,138,4151,183,2304,56,882,727,181,136],"class_list":["post-1925","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-acetylsalicylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-antikoagulanzien","tag-apixaban","tag-apoplektischer-insult","tag-appraise-studie","tag-arrhythmien","tag-ass","tag-azetylsalizylsaeure","tag-blutungsrisiko","tag-cha2ds2-vasc-score","tag-clopidogrel","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-has-bled-score","tag-herzinfarkt","tag-herzrhythmusstoerungen","tag-hirninfarkt","tag-koronar-stent","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-neue-orale-antikoagulanzien","tag-noak","tag-phenprocoumon","tag-re-deem-studie","tag-rhythmusstoerungen","tag-rivaroxaban","tag-schlaganfall","tag-stent","tag-thrombozytenaggregationshemmer","tag-vorhofflimmern","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1925"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1925\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}